SCHEMBL376602

SCHEMBL376602

N/C(=N\S(=O)(=O)c1ccc(F)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC=C(c3ccccc3)c3ccccc3)CC2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.42
LMNA P02545 5/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
BCL2L1 Q07817 3/20 0.42
BCL2 P10415 2/20 0.42
CTSK P43235 1/20 0.41
MEN1 O00255 4/20 0.39
KMT2A Q03164 4/20 0.39
GAA P10253 3/20 0.39
MAPT P10636 7/20 0.38
MAPK1 P28482 3/20 0.38
L3MBTL1 Q9Y468 3/20 0.38
RECQL P46063 1/20 0.38
POLB P06746 1/20 0.38
HTT P42858 3/20 0.37
TP53 P04637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HTR1A P08908 1/20 0.36
NPSR1 Q6W5P4 2/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL376603 1.00 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2BCL2L1BCL2
SCHEMBL13503543 1.00 ALDH1A1 (0.42) ALDH1A1LMNASMN1; SMN2BCL2L1BCL2
SCHEMBL376435 0.90 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2BCL2L1BCL2
SCHEMBL13503908 0.90 ALDH1A1 (0.52) ALDH1A1LMNASMN1; SMN2BCL2L1BCL2
SCHEMBL13503981 0.87 MAPT (0.37) ALDH1A1LMNASMN1; SMN2BCL2L1BCL2
SCHEMBL376604 0.84 BCL2L1 (0.46) ALDH1A1LMNASMN1; SMN2BCL2L1BCL2
SCHEMBL3589313 0.83 BCL2L1 (0.58) BCL2L1BCL2
SCHEMBL13503607 0.83 BCL2L1 (0.58) BCL2L1BCL2
SCHEMBL376618 0.83 BCL2L1 (0.58) BCL2L1BCL2
SCHEMBL3601745 0.81 BCL2L1 (0.58) BCL2L1BCL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765778-B1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2012-01-25 EP disclosed
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES 2010-02-11 US disclosed
US-7585858-B2 N-sulfonylcarboximidamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-09-08 US disclosed
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters ABBVIE INC. 2005-12-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100035879-A1 N-SULFONYLCARBOXIMIDAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BAD ALDH1A1 2354/4885LMNA 141/4885SMN1; SMN2 808/4885
US-20050272744-A1 N-sulfonylcarboximidamide apoptosis promoters BAX, BCL2, BAD ALDH1A1 2354/4885LMNA 141/4885SMN1; SMN2 808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.